Vincenzi Bruno, Badalamenti Giuseppe, Napolitano Andrea, Spalato Ceruso Mariella, Pantano Francesco, Grignani Giovanni, Russo Antonio, Santini Daniele, Aglietta Massimo, Tonini Giuseppe
Medical Oncology Department, Campus Bio-Medico, University of Rome, Rome, Italy.
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.
Crit Rev Oncol Hematol. 2017 Oct;118:1-6. doi: 10.1016/j.critrevonc.2017.06.006. Epub 2017 Jul 15.
Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
晚期软组织肉瘤是侵袭性癌症，治疗选择有限。最近，单克隆抗体olaratumab抑制血小板衍生生长因子受体（PDGFR）-α显示出有前景的临床活性。如果得到证实，这将是首个在晚期软组织肉瘤治疗中有效的靶向治疗实例之一，且与组织学亚型无关。在此，我们回顾了血小板衍生生长因子（PDGF）/PDGFR轴的生物学特性，尤其关注其在癌症中的作用，然后讨论了PDGFR-α抑制在晚期软组织肉瘤治疗中的效果。
Zotero 插件